Chiron inhales

In the rush to realize the theoretical advantages of inhaled delivery, companies with marketed therapeutics sometimes form partnerships with more than one inhaled delivery company to develop different technologies in parallel, or engage in sequential partnering in their search for a successful technology.

But the delivery companies themselves can affect the partnering landscape by tackling projects for their own accounts, often in the hope of having data in hand to show a potential partner. Such was the case with Inhale Therapeutic Systems Inc., which won over Chiron Corp. as a partner for its inhaled version of the antibiotic tobramycin...